Scilex Holding Company (SCLXW)Palo Alto, United States | NasdaqCM
0.06 USD
+0.06
(0.000%)
⇧
(Oct. 13, 2026, 3:03 p.m.
EDT)
After hours: 0.08 +0.02 (35.910%) ⇧ (Oct. 13, 2026, 6:18 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 7:06 a.m. EDT
The immediate outlook is severely bearish as the security trades at its 52-week low, having recently slid nearly 10% and tested critical support levels amid thin volume. The technical picture suggests a breakdown rather than a bounce, with the price hovering near the absolute floor of its range. From a long-term perspective, this instrument is a catastrophic value trap; the company reports negative revenue growth of 22.8%, generates massive operating losses, and possesses a negative book value of over $43 per share. The balance sheet is insolvent, with debt exceeding $105 million against only $581k in cash and a current ratio of 0.07, indicating imminent liquidity crisis. Furthermore, the company is mired in legal proceedings regarding a bankruptcy court extension of a lockup period, signaling deep structural distress. There is no dividend to provide income, and the lack of price history combined with deteriorating fundamentals makes holding this position untenable. |
| Attribute | Value |
|---|---|
| Revenue per Share | 3.637 |
| Beta | 1.79 |
| Website | https://www.scilexholding.com |
| Attribute | Value |
|---|---|
| Address1 | 960 San Antonio Road |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | 1.792 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | -43.829 |
| City | Palo Alto |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.0622 |
| Current Ratio | 0.071 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.0738 |
| Day Low | 0.0425 |
| Ebitda | -277,268,000 |
| Ebitda Margins | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.0738 |
| Fifty Two Week High Change | -0.011599999 |
| Fifty Two Week High Change Percent | -0.15718156 |
| Fifty Two Week Low | 0.0425 |
| Fifty Two Week Low Change | 0.019699998 |
| Fifty Two Week Low Change Percent | 0.46352938 |
| Fifty Two Week Range | 0.0425 - 0.0738 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,784,295,000,000 |
| Float Shares | 5,690,117 |
| Free Cashflow | -8,842,550 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 34 |
| Fullday Change | 0.0119 |
| Fullday Change Percent | 16.413794 |
| Fullday Price | 0.0844 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.55495 |
| Gross Profits | 17,541,000 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Language | en-US |
| Long Business Summary | Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California. |
| Long Name | Scilex Holding Company |
| Market | us_market |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_607715156 |
| Net Income To Common | -448,344,992 |
| Open | 0.17 |
| Operating Cashflow | -17,085,000 |
| Operating Margins | -3.85017 |
| Phone | 650 516 4310 |
| Post Market Change | 0.022299998 |
| Post Market Change Percent | 35.90982 |
| Post Market Price | 0.0844 |
| Post Market Time | 1,791,929,903 |
| Previous Close | 0.0 |
| Price Hint | 4 |
| Price To Book | -0.0014191517 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.051 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0622 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.0738 |
| Regular Market Day Low | 0.0425 |
| Regular Market Day Range | 0.0425 - 0.0738 |
| Regular Market Open | 0.17 |
| Regular Market Previous Close | 0.0 |
| Regular Market Price | 0.0622 |
| Regular Market Time | 1,791,918,187 |
| Regular Market Volume | 40 |
| Return On Assets | -1.0583 |
| Revenue Growth | -0.228 |
| Revenue Per Share | 3.637 |
| Sand P52 Week Change | 0.17004645 |
| Sector | |
| Sector Key | |
| Source Interval | 15 |
| State | CA |
| Symbol | SCLXW |
| Total Cash | 581,000 |
| Total Cash Per Share | 0.083 |
| Total Debt | 105,985,000 |
| Total Revenue | 31,608,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 40 |
| Website | https://www.scilexholding.com |
| Zip | 94,303 |